Viewing Study NCT03931668


Ignite Creation Date: 2025-12-24 @ 5:30 PM
Ignite Modification Date: 2025-12-24 @ 5:30 PM
Study NCT ID: NCT03931668
Status: UNKNOWN
Last Update Posted: 2019-12-23
First Post: 2019-04-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Tolerance, PK and PD Effects Study of TPN-672 in Chinese Healthy Volunteers
Sponsor: Shanghai Mental Health Center
Organization:

Study Overview

Official Title: A Single Site, Randomized, Double-blind, Placebo-controlled, Incremental Phase I Clinical Trial: to Evaluate the Tolerance, PK and PD Effects of TPN-672 Maleate in Chinese Healthy Volunteers After Single Dose Administration.
Status: UNKNOWN
Status Verified Date: 2019-04
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a single-site, randomized, double-blind, placebo-controlled, incremental phase I clinical trial to evaluate preliminarily the tolerance, pharmacokinetics and pharmacodynamic effects of TPN672 maleate in Chinese healthy volunteers after single dose administration.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
TPN672-KYHY-201801 OTHER Kanion Pharmaceutical View